Stay updated with breaking news from Trial Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...
Trial for Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups. Findings from the Phase 2 Clinical Trial: The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older, at 16 U.S. sites. Participants received either INO-4800 (1.0 mg or 2.0 mg dose) or placebo at 0 and 4 weeks (randomized 3:3:1:1). Each dose was administered by intradermal injection followed by electroporation using INOVIO's CELLECTR...
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021 News provided by Share this article Share this article PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19. A live and archived ...
Share this article Share this article PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear ...
10 Best Biotech Stocks Under $6 in 2021 The global biotechnology sector is expected to grow to more than $2.5 trillion by the end of this decade. The growth in the industry is expected to be driven by innovation, research, and new scientific discoveries. There is plenty of reason to be hopeful about the future of biotechnology, one of the core ones being the performance of the sector in 2020, a year ravaged by the worst pandemic in more than hundred years that took the lives of millions across the world. Even through the grim twelve months, the biotech sector exceeded market expectations. I...